The Journal of Practical Medicine >
Effect of lncRNA MIF⁃AS1 on the malignant biological behavior of prostate cancer cells by regulating the miR⁃423⁃5p/PYCR1 axis
Received date: 2023-11-28
Online published: 2024-09-30
Objective To investigate the effect of long non-coding RNA （lncRNA） macrophage migration inhibitory factor antisense RNA1 （MIF-AS1） on the malignant biological behavior of prostate cancer （PC） cells by regulating the miR-423-5p/pyrroline-5-carboxylic acid reductase 1 （PYCR1） axis. Methods PC3 cells were cultured in vitro to knock down the expression of MIF-AS1 or down-regulate the expression of miR-423-5p. The expression of MIF-AS1， miR-423-5p and PYCR1 mRNA in tumor tissues and adjacent tissues and cells of PC patients were detected. The cell proliferation， apoptosis， migration， and invasion were detected and the expression of PYCR1 protein was detected by Western blot. The relationships between miR-423-5p， IF-AS1 and PYCR1 were verified. Results The MIF-AS1 and PYCR1 mRNA were observed to be highly expressed in the tumor tissues， while miR-423-5p was lowly expressed. Silenced MIF-AS1 inhibited the proliferation， migration and invasion of PC3 cells and up-regulated miR-423-5p induced cell apoptosis （P < 0.05）. Inhibition of miR-423-5p expression reversed the inhibitory effect of silencing MIF-AS1 on malignant behavior of PC3 cells （P < 0.05）. miR-423-5p was correlated with MIF-AS1 and PYCR1 by targeted regulation. Conclusion Silencing MIF-AS1 may inhibit the expression of PYCR1 by up-regulating miR-423-5p， thereby inhibiting the malignant behavior of PC cells.
Jianbo YANG , Jichun SHAO , Zhijun ZENG , Tao ZHAO , Xing. WANG . Effect of lncRNA MIF⁃AS1 on the malignant biological behavior of prostate cancer cells by regulating the miR⁃423⁃5p/PYCR1 axis[J]. The Journal of Practical Medicine, 2024 , 40(18) : 2544 -2549 . DOI: 10.3969/j.issn.1006-5725.2024.18.006
| 1 | RAFIKOVA G， GILYAZOVA I， ENIKEEVA K， et al. Prostate Cancer： Genetics， Epigenetics and the Need for Immunological Biomarkers［J］. Int J Mol Sci， 2023， 24（16）：12797. doi:10.3390/ijms241612797 |
| 2 | BERGENGREN O， PEKALA K R， MATSOUKAS K， et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review［J］. Eur Urol， 2023， 84（2）：191-206. doi:10.1016/j.eururo.2023.04.021 |
| 3 | SEKHOACHA M， RIET K， MOTLOUNG P， et al. Prostate Cancer Review： Genetics， Diagnosis， Treatment Options， and Alternative Approaches［J］. Molecules， 2022， 27（17）：5730-5742. doi:10.3390/molecules27175730 |
| 4 | WU M， HUANG Y， CHEN T， et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis［J］. J Cell Mol Med， 2019， 23（1）：29-38. doi:10.1111/jcmm.13658 |
| 5 | TAN Y T， LIN J F， LI T， et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer［J］. Cancer Commun （Lond）， 2021， 41（2）：109-120. doi:10.1002/cac2.12108 |
| 6 | LI L， LI Y， HUANG Y， et al. Long non-coding RNA MIF-AS1 promotes gastric cancer cell proliferation and reduces apoptosis to upregulate NDUFA4［J］. Cancer Sci， 2018， 109（12）：3714-3725. doi:10.1111/cas.13801 |
| 7 | WANG B， ZHANG Y， YE M， et al. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner［J］. Curr Drug Metab， 2019， 20（10）：804-814. doi:10.2174/1389200220666190819151946 |
| 8 | FERRI C， DI BIASE A， BOCCHETTI M， et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer［J］. J Exp Clin Cancer Res， 2022， 41（1）：20-32. doi:10.1186/s13046-021-02233-w |
| 9 | KAY E J， PATERSON K， RIERA-DOMINGO C， et al. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix［J］. Nat Metab， 2022， 4（6）：693-710. doi:10.1038/s42255-022-00582-0 |
| 10 | 张丽红， 胡良峰， 杨烨， 等. PYCR1在肝癌中的表达特点及其临床价值［J］. 医学研究杂志， 2023， 52（2）：76-80. |
| 11 | SCHATTEN H. Brief overview of prostate cancer statistics， grading， diagnosis and treatment strategies［J］. Adv Exp Med Biol， 2018， 1095（1）：1-14. |
| 12 | VIETRI M T， D'ELIA G， CALIENDO G， et al. Hereditary prostate cancer： Genes related， target therapy and prevention［J］. Int J Mol Sci， 2021， 22（7）：3753-3762. doi:10.3390/ijms22073753 |
| 13 | MCCABE E M， RASMUSSEN T P. lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions［J］. Semin Cancer Biol， 2021， 75（1）：38-48. doi:10.1016/j.semcancer.2020.12.012 |
| 14 | HAGHIGHI R， CASTILLO-ACOBO R Y， AMIN A H， et al. A thorough understanding of the role of lncRNA in prostate cancer pathogenesis； Current knowledge and future research directions［J］. Pathol Res Pract， 2023， 248：154666. doi:10.1016/j.prp.2023.154666 |
| 15 | YANG G， LI T， LIU J， et al. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis［J］. Genomics， 2023， 115（2）：110599. doi:10.1016/j.ygeno.2023.110599 |
| 16 | NI P， WANG G， WANG Y， et al. Correlation of MIF-AS1 polymorphisms with the risk and prognosis of gastric cancer［J］. Pathol Res Pract， 2022， 233（1）：153-163. doi:10.1016/j.prp.2022.153850 |
| 17 | FAN Y， WANG L， HAN X C， et al. LncRNA MIF-AS1 aggravates the progression of ovarian cancer by sponging miRNA-31-5p［J］. Eur Rev Med Pharmacol Sci， 2020， 24（5）：2248-2255. |
| 18 | GUO Y， ZHOU X， GAO F， et al. MiR-423-5p is a novel endogenous control for the quantification of circulating miRNAs in human esophageal squamous cell carcinoma［J］. Heliyon， 2023， 9（4）：e14515. doi:10.1016/j.heliyon.2023.e14515 |
| 19 | WANG Q， WANG L X， ZHANG C Y， et al. LncRNA CRNDE promotes cell proliferation， migration and invasion of ovarian cancer via miR-423-5p/FSCN1 axis［J］. Mol Cell Biochem， 2022， 477（5）：1477-1488. doi:10.1007/s11010-022-04382-8 |
| 20 | JIANG F， HU X， CAO H， et al. Hsa_circ_0000081 promotes the function of gastric cancer through sponging hsa-miR-423-5p to influence 3-phosphoinositide-dependent kinase 1 expression［J］. Bioengineered， 2022， 13（4）：8277-8290. doi:10.1080/21655979.2022.2053796 |
| 21 | XUE S T， ZHENG B， CAO S Q， et al. Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis［J］. Mol Cancer， 2022， 21（1）：69-78. doi:10.1186/s12943-022-01539-3 |
| 22 | SHANG Y， WANG L， ZHU Z， et al. Downregulation of miR-423-5p Contributes to the Radioresistance in Colorectal Cancer Cells［J］. Front Oncol， 2021， 10（1）：582-590. doi:10.3389/fonc.2020.582239 |
| 23 | CUI B， HE B， HUANG Y， et al. Pyrroline-5-carboxylate reductase 1 reprograms proline metabolism to drive breast cancer stemness under psychological stress［J］. Cell Death Dis， 2023， 14（10）：682. doi:10.1038/s41419-023-06200-5 |
| 24 | 程秋华， 周帅， 向杨， 等. PYCR1基因在肝细胞癌中的表达及与预后的关系［J］. 实用医学杂志， 2021， 37（2）：233-237. |
| 25 | DU S， SUI Y， REN W， et al. PYCR1 promotes bladder cancer by affecting the Akt/Wnt/β-catenin signaling［J］. J Bioenerg Biomembr， 2021， 53（2）：247-258. doi:10.1007/s10863-021-09887-3 |
| 26 | XU H， HE Y， LIN L， et al. MiR-1207-5p targets PYCR1 to inhibit the progression of prostate cancer［J］. Biochem Biophys Res Commun， 2021， 575：56-64. doi:10.1016/j.bbrc.2021.08.037 |
/
| 〈 |
|
〉 |